We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Drug Delivery System Capitalizes on Monocytes' Ability to Penetrate Areas of Inflammation

By LabMedica International staff writers
Posted on 18 Jan 2015
A novel experimental drug delivery system is based on disc-shaped polymeric microparticles that are attached to monocytes, white blood cells that possess a unique ability to target and penetrate into sites of inflammation.

Investigators at the University of California, Santa Barbara (UCSB; USA) and colleagues at the Massachusetts Institute of Technology (Cambridge, MA, USA) selected the disc shape, since a nonspherical flexible shape is more durable and resistant to phagocytosis than is a rigid spherical particle. More...


In a paper published in the December 3, 2014, online edition of the Journal of Controlled Release, the investigators described how they capitalized on the natural ability of monocytes to target and deliver flat polymeric particles, which they called "cellular backpacks," to inflamed tissues. The cellular backpacks attached strongly to the surface of monocytes but did not undergo phagocytosis. Following attachment of backpacks, monocytes retained important cellular functions including transmigration through an endothelial monolayer and differentiation into macrophages.

In future experiments, cellular backpacks loaded with drugs will be injected into the bloodstream, whereupon they should attach to circulating monocytes and "hitchhike" to the target region. At the site of inflammation, the particles will degrade and release their drugs.

"Basically the main benefit is that you can deliver the drug in a more effective dose," said senior author Dr. Samir Mitragotri, professor of chemical engineering at the UCSB. "Take, for example, the case of chemotherapy, which often has a narrow therapeutic range: too little and the treatment is not effective, too much and it can be lethal. Because chemo travels through the bloodstream and affects all the tissues it comes in contact with, dosages are restricted at least in part based on the deleterious effect it has on other, unafflicted organs and their functions. Not only can targeted therapy ensure other body systems remain unaffected, but it could allow for higher doses of drug to the site, which could decrease treatment time. Many diseases result in inflammation. If we could target the common denominator, whether the inflammation is coming from cancer or arthritis, we could deliver the drug there."

Related Links:
University of California, Santa Barbara
Massachusetts Institute of Technology



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.